| Michael Osnard, | |
|
600 N Wolfe St, Baltimore, MD 21287-0005 | |
| (216) 844-2562 | |
| Not Available |
| Full Name | Michael Osnard |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 7 Years |
| Location | 600 N Wolfe St, Baltimore, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780115956 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | D89585 (Maryland) | Primary |
| 207R00000X | Internal Medicine | MD-47389 (Iowa) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Johns Hopkins Hospital, The | Baltimore, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Johns Hopkins University | 4981745098 | 571 |
News Archive
In chronic viral infections and cancer, T cell dysfunction is sure to be observed. A new study to be published in the journal Immunity shows that before these cells are completely exhausted, there is a transitory stage in which some cells are present with features that are characteristic of neither the stem-like T cells nor the mature but exhausted T cells.
Compared to standard machine learning models, deep learning models are largely superior at discerning patterns and discriminative features in brain imaging, despite being more complex in their architecture, according to a new study in Nature Communications led by Georgia State University.
Cephalon, Inc. confirmed today that it received an unsolicited proposal from Valeant Pharmaceuticals International, Inc., on March 18th to acquire the Company for $73 per share and a second unsolicited proposal on March 25th to either acquire the Company for $73 per share or to purchase Cephalon's non-oncology related assets for $2.8 billion. On March 29th, Valeant announced an unsolicited proposal to acquire all of the outstanding shares in the Company for $73 per share.
Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt released the following statement today on a new study published in the Journal of the American Medical Association that found "implementation of Medicare Part D was followed by a significant reductions in nondrug medical spending, particularly on acute and post acute care, for elderly Medicare beneficiaries with limited prior drug coverage".
Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc. today announced that Genzyme has submitted a marketing authorization application (MAA) to the European Medicines Agency seeking approval for the 200 mg weekly dose of mipomersen for the treatment of homozygous and severe heterozygous familial hypercholesterolemia.
› Verified 5 days ago
| Entity Name | Johns Hopkins University |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1902332133 PECOS PAC ID: 4981745098 Enrollment ID: O20170818000085 |
News Archive
In chronic viral infections and cancer, T cell dysfunction is sure to be observed. A new study to be published in the journal Immunity shows that before these cells are completely exhausted, there is a transitory stage in which some cells are present with features that are characteristic of neither the stem-like T cells nor the mature but exhausted T cells.
Compared to standard machine learning models, deep learning models are largely superior at discerning patterns and discriminative features in brain imaging, despite being more complex in their architecture, according to a new study in Nature Communications led by Georgia State University.
Cephalon, Inc. confirmed today that it received an unsolicited proposal from Valeant Pharmaceuticals International, Inc., on March 18th to acquire the Company for $73 per share and a second unsolicited proposal on March 25th to either acquire the Company for $73 per share or to purchase Cephalon's non-oncology related assets for $2.8 billion. On March 29th, Valeant announced an unsolicited proposal to acquire all of the outstanding shares in the Company for $73 per share.
Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt released the following statement today on a new study published in the Journal of the American Medical Association that found "implementation of Medicare Part D was followed by a significant reductions in nondrug medical spending, particularly on acute and post acute care, for elderly Medicare beneficiaries with limited prior drug coverage".
Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc. today announced that Genzyme has submitted a marketing authorization application (MAA) to the European Medicines Agency seeking approval for the 200 mg weekly dose of mipomersen for the treatment of homozygous and severe heterozygous familial hypercholesterolemia.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Osnard, 6201 Greenleigh Ave, Middle River, MD 21220-2004 Ph: (410) 933-6423 | Michael Osnard, 600 N Wolfe St, Baltimore, MD 21287-0005 Ph: (216) 844-2562 |
News Archive
In chronic viral infections and cancer, T cell dysfunction is sure to be observed. A new study to be published in the journal Immunity shows that before these cells are completely exhausted, there is a transitory stage in which some cells are present with features that are characteristic of neither the stem-like T cells nor the mature but exhausted T cells.
Compared to standard machine learning models, deep learning models are largely superior at discerning patterns and discriminative features in brain imaging, despite being more complex in their architecture, according to a new study in Nature Communications led by Georgia State University.
Cephalon, Inc. confirmed today that it received an unsolicited proposal from Valeant Pharmaceuticals International, Inc., on March 18th to acquire the Company for $73 per share and a second unsolicited proposal on March 25th to either acquire the Company for $73 per share or to purchase Cephalon's non-oncology related assets for $2.8 billion. On March 29th, Valeant announced an unsolicited proposal to acquire all of the outstanding shares in the Company for $73 per share.
Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt released the following statement today on a new study published in the Journal of the American Medical Association that found "implementation of Medicare Part D was followed by a significant reductions in nondrug medical spending, particularly on acute and post acute care, for elderly Medicare beneficiaries with limited prior drug coverage".
Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc. today announced that Genzyme has submitted a marketing authorization application (MAA) to the European Medicines Agency seeking approval for the 200 mg weekly dose of mipomersen for the treatment of homozygous and severe heterozygous familial hypercholesterolemia.
› Verified 5 days ago
Allison Weaver, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 600 N Wolfe Street, Meyer 8-134, Baltimore, MD 21287 Phone: 410-614-4474 Fax: 410-367-2770 | |
Cheryl Myers Hepp, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 22 S Greene St, Baltimore, MD 21201 Phone: 410-328-2882 Fax: 410-328-7607 | |
Omid Sanaei, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 201 E University Pkwy, Baltimore, MD 21218 Phone: 410-554-2284 Fax: 410-554-2184 | |
Sumedha Nallamothu, M.B.B.S Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 600 N Wolfe Street, Meyer 8-134, Baltimore, MD 21287 Phone: 410-614-4474 Fax: 410-367-2770 | |
Dr. Nejat Ahmed Mohammed, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 3001 S Hanover St, Baltimore, MD 21225 Phone: 410-350-3200 | |
Mahyar Toofantabrizi, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 9000 Franklin Square Dr, Baltimore, MD 21237 Phone: 443-777-7000 | |
Lee-ann Marie Wagner, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 22 S Greene St, Baltimore, MD 21201 Phone: 410-328-2882 Fax: 410-328-7607 |